HMDB0004684 | 11,12,15-THETA | | | C20H34O5 | 354.481 354.240624198 | Not Available |
HMDB0004673 | 11,12-Epoxyeicosatrienoic acid | 123931-40-8 | | C20H32O3 | 320.473 320.23514489 | Not Available |
HMDB0004694 | 11,14,15-THETA | | | C20H34O5 | 354.481 354.240624198 | Not Available |
HMDB0004693 | 11H-14,15-EETA | 219535-29-2 | | C20H32O4 | 336.4657 336.230059512 | Not Available |
HMDB0004702 | 12,13-EpOME | | | C18H32O3 | 296.4449 296.23514489 | Not Available |
HMDB0013911 | 12-Hydroxynevirapine | | | C15H14N4O2 | 282.2973 282.111675712 | - Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
|
HMDB0004264 | 14,15-Epoxy-5,8,11-eicosatrienoic acid | 81276-03-1 | | C20H32O3 | 320.4663 320.23514489 | Not Available |
HMDB0004244 | 15(S)-HPETE | 70981-96-3 | | C20H32O4 | 336.4657 336.230059512 | Not Available |
HMDB0005050 | 15H-11,12-EETA | 877878-78-9 | | C20H32O4 | 336.4657 336.230059512 | Not Available |
HMDB0004680 | 16(R)-HETE | | | C20H32O3 | 320.4663 320.23514489 | Not Available |
HMDB0011136 | 19(S)-HETE | 79551-85-2 | | C20H32O3 | 320.4663 320.23514489 | Not Available |
HMDB0003955 | 19-Hydroxyandrost-4-ene-3,17-dione | 510-64-5 | | C19H26O3 | 302.4079 302.188194698 | Not Available |
HMDB0006769 | 19-Hydroxytestosterone | 2126-37-6 | | C19H28O3 | 304.4238 304.203844762 | Not Available |
HMDB0006768 | 19-Oxoandrost-4-ene-3,17-dione | | | C19H24O3 | 300.3921 300.172544634 | Not Available |
HMDB0003959 | 19-Oxotestosterone | 4075-13-2 | | C19H26O3 | 302.4079 302.188194698 | Not Available |
HMDB0013929 | 2-Oxoclopidogrel | | | C16H16ClNO3S | 337.821 337.05394178 | - Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
|
HMDB0013895 | 3',4'-Dihydrodiol | | | C15H14N2O4 | 286.2827 286.095356946 | - Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
|
HMDB0013858 | 3-Dechloroethylifosfamide | 36761-83-8 | | C5H12ClN2O2P | 198.588 198.032491857 | - Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
- Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. [PubMed:16702183 ]
- Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66. [PubMed:10348794 ]
|
HMDB0013897 | 4-ene-Valproic acid | | | C8H14O2 | 142.1956 142.099379692 | - Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
|
HMDB0002190 | 5,6-Epoxy-8,11,14-eicosatrienoic acid | 81246-84-6 | | C20H32O3 | 320.4663 320.23514489 | Not Available |
HMDB0004081 | 6-Hydroxymelatonin | 2208-41-5 | | C13H16N2O3 | 248.2777 248.116092388 | Not Available |
HMDB0003956 | 7a-Hydroxytestosterone | 2141-17-5 | | C19H28O3 | 304.4238 304.203844762 | Not Available |
HMDB0002232 | 8,9-Epoxyeicosatrienoic acid | 81246-85-7 | | C20H32O3 | 320.4663 320.23514489 | Not Available |
HMDB0004701 | 9,10-Epoxyoctadecenoic acid | | | C18H32O3 | 296.4449 296.23514489 | Not Available |
HMDB0014940 | Alfentanil | 71195-58-9 | | C21H32N6O3 | 416.5172 416.25358892 | - Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Klees TM, Sheffels P, Dale O, Kharasch ED: Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug Metab Dispos. 2005 Mar;33(3):303-11. Epub 2004 Nov 22. [PubMed:15557344 ]
- Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D: Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007 Oct;82(4):410-26. Epub 2007 Jun 6. [PubMed:17554244 ]
- Klees TM, Sheffels P, Thummel KE, Kharasch ED: Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology. 2005 Mar;102(3):550-6. [PubMed:15731592 ]
|